Systemic manifestation and co-morbidity in chronic obstructive pulmonary disease (COPD) are associated with circulating markers of aging: a cross-sectional observational study with a longitudinal follow-up for two years

Dutch Asthma Foundation (Netherlands)0 个研究点目标入组 600 人开始时间: 2010年5月18日最近更新: 2015年1月13日

试验速览

暂无简介。

•COPD patients:
•1. Diagnosis of COPD according to the American Thoracic Society (ATS) Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (forced expiratory volume in one second [FEV1] less than 80% predicted and FEV1/forced vital capacity [FVC] less than 70% and less than 10% predicted improvement in FEV1 after ?Ò2-agonist inhalation
•2. Both male and female, aged from 50 to 75 years
•3. No respiratory tract infection or exacerbation of the disease for less than 4 weeks before the study
•4. Capable of providing informed consent
•Healthy subjects:
•1. Healthy subjects as judged by a physician
•2. Without diagnosed COPD or any other described co-morbidity/chronic disease
•3. Both male and female, aged from 50 to 75 years

•COPD patients:
•1. Any kind of carcinogenic pathology less than 5 years before study participation
•2. Participation in any other studies involving investigational or marketed products concomitantly or less than 4 weeks prior to entry into the study
•Healthy subjects:
•1. Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements
•2. Participation in any other study involving investigational or marketed products concomitantly or within two weeks prior to entry into the study

发起方

Dutch Asthma Foundation (Netherlands)